These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 27444035)

  • 1. Serous ovarian and primary peritoneal cancers: A comparative analysis of clinico-pathological features, molecular subtypes and treatment outcome.
    Gao B; Lindemann K; Anderson L; Fereday S; Hung J; Alsop K; Tothill RW; Gebski V; Kennedy C; Balleine RL; ; Harnett PR; Bowtell DD; DeFazio A
    Gynecol Oncol; 2016 Sep; 142(3):458-64. PubMed ID: 27444035
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BRCA mutational status, initial disease presentation, and clinical outcome in high-grade serous advanced ovarian cancer: a multicenter study.
    Petrillo M; Marchetti C; De Leo R; Musella A; Capoluongo E; Paris I; Benedetti Panici P; Scambia G; Fagotti A
    Am J Obstet Gynecol; 2017 Sep; 217(3):334.e1-334.e9. PubMed ID: 28549976
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognosis of stage III or IV primary peritoneal serous papillary carcinoma.
    Dubernard G; Morice P; Rey A; Camatte S; Fourchotte V; Thoury A; Pomel C; Pautier P; Lhommé C; Duvillard P; Castaigne D
    Eur J Surg Oncol; 2004 Nov; 30(9):976-81. PubMed ID: 15498644
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ascites regression following neoadjuvant chemotherapy in prediction of treatment outcome among stage IIIc to IV high-grade serous ovarian cancer.
    Xu X; Deng F; Lv M; Ren B; Guo W; Chen X
    J Ovarian Res; 2016 Dec; 9(1):85. PubMed ID: 27912779
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [CA 125 regression after two cycles of neoadjuvant chemotherapy as prognostic factor in patients with advanced ovarian cancer and primary peritoneal serous cancer who underwent interval surgical cytoreduction].
    Gasowska-Bodnar A; Bodnar L; Wcisło GB; Jerzak MM; Szczylik C; Baranowski W
    Ginekol Pol; 2008 Feb; 79(2):108-14. PubMed ID: 18510089
    [TBL] [Abstract][Full Text] [Related]  

  • 6. External validation of a 'response score' after neoadjuvant chemotherapy in patients with high-grade serous ovarian carcinoma with complete clinical response.
    Zorzato PC; Zannoni GF; Tudisco R; Pasciuto T; Di Giorgio A; Franchi M; Scambia G; Fagotti A
    Int J Gynecol Cancer; 2020 Jan; 30(1):67-73. PubMed ID: 31754067
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Primary cytoreductive surgery compared with neoadjuvant chemotherapy in patients with
    Kim SR; Parbhakar A; Li X; Bernardini MQ; Hogen L; May T
    Int J Gynecol Cancer; 2024 Jun; 34(6):879-885. PubMed ID: 38548312
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potential utility of pretreatment serum miRNAs for optimal treatment selection in advanced high-grade serous ovarian cancer.
    Uehara T; Matsuzaki J; Yoshida H; Ogawa Y; Miura J; Fujimiya H; Yamamoto Y; Kawauchi J; Takizawa S; Yonemori K; Sakamoto H; Kato K; Ishikawa M; Ochiya T
    Jpn J Clin Oncol; 2024 Aug; 54(8):917-925. PubMed ID: 38651188
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The number of cycles of neoadjuvant chemotherapy is associated with prognosis of stage IIIc-IV high-grade serous ovarian cancer.
    Xu X; Deng F; Lv M; Chen X
    Arch Gynecol Obstet; 2017 Feb; 295(2):451-458. PubMed ID: 27913927
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of increased utilization of neoadjuvant chemotherapy on survival in patients with advanced ovarian cancer: experience from a comprehensive cancer center.
    Lee YJ; Chung YS; Lee JY; Nam EJ; Kim SW; Kim S; Kim YT
    J Gynecol Oncol; 2018 Jul; 29(4):e63. PubMed ID: 29770632
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognosis for advanced-stage primary peritoneal serous papillary carcinoma and serous ovarian cancer in Taiwan.
    Chao KC; Chen YJ; Juang CM; Lau HY; Wen KC; Sung PL; Fang FY; Twu NF; Yen MS
    Taiwan J Obstet Gynecol; 2013 Mar; 52(1):81-4. PubMed ID: 23548224
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Uptake and Outcomes of Neoadjuvant Chemotherapy Among US Patients With Less Common Epithelial Ovarian Carcinomas.
    Matsuo K; Matsuzaki S; Maeda M; Rau AR; Yoshihara K; Tamura R; Shimada M; Machida H; Mikami M; Klar M; Roman LD; Wright JD; Sood AK; Gershenson DM
    JAMA Netw Open; 2023 Jun; 6(6):e2318602. PubMed ID: 37326992
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of complete cytoreduction leaving no gross residual disease associated with radical cytoreductive surgical procedures on survival in advanced ovarian cancer.
    Chang SJ; Bristow RE; Ryu HS
    Ann Surg Oncol; 2012 Dec; 19(13):4059-67. PubMed ID: 22766983
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Treatment and prognostic analysis of ovarian cancer patients with isolated region of lymph node recurrence].
    Tu H; Huang H; Huang QD; Li Z; Feng YL; Liu JH
    Zhonghua Fu Chan Ke Za Zhi; 2012 Dec; 47(12):928-33. PubMed ID: 23324194
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HIPEC after neoadjuvant chemotherapy and interval debulking is associated with development of platinum-refractory or -resistant disease.
    Jou J; Zimmer Z; Charo L; Yau C; Saenz C; Eskander R; McHale M; Veerapong J; Plaxe S; Binder P
    Gynecol Oncol; 2021 Apr; 161(1):25-33. PubMed ID: 33293046
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic significance of postoperative morbidities in patients with advanced epithelial ovarian cancer treated with neoadjuvant chemotherapy and delayed primary surgical debulking.
    Le T; Alshaikh G; Hopkins L; Faught W; Fung MF
    Ann Surg Oncol; 2006 Dec; 13(12):1711-6. PubMed ID: 17009146
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic implications of histological tumor regression (Böhm's score) in patients receiving neoadjuvant chemotherapy for high grade serous tubal & ovarian carcinoma.
    Rajkumar S; Polson A; Nath R; Lane G; Sayasneh A; Jakes A; Begum S; Mehra G
    Gynecol Oncol; 2018 Nov; 151(2):264-268. PubMed ID: 30197060
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neoadjuvant chemotherapy for low-grade serous carcinoma of the ovary or peritoneum.
    Schmeler KM; Sun CC; Bodurka DC; Deavers MT; Malpica A; Coleman RL; Ramirez PT; Gershenson DM
    Gynecol Oncol; 2008 Mar; 108(3):510-4. PubMed ID: 18155273
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcomes of Non-High Grade Serous Carcinoma after Neoadjuvant Chemotherapy for Advanced-Stage Ovarian Cancer: Single-Institution Experience.
    Chung YS; Lee JY; Kim HS; Nam EJ; Kim SW; Kim YT
    Yonsei Med J; 2018 Oct; 59(8):930-936. PubMed ID: 30187699
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic significance of supraclavicular lymphadenopathy in patients with high-grade serous ovarian cancer.
    Cybulska P; Hayes SA; Spirtos A; Rafizadeh MJ; Filippova OT; Leitao M; Zivanovic O; Sonoda Y; Mueller J; Lakhman Y; Long K; Chi DS
    Int J Gynecol Cancer; 2019 Nov; 29(9):1377-1380. PubMed ID: 31575614
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.